Rogelio Santos, Jr. is the co-founder, Chairman and CEO of Amylex. Under his leadership, he successfully developed and led the company towards its first FDA approval. Santos has also founded companies including a multinational software development and digital media firm, a national real-estate technology services agency, a non-profit organization and a web-based construction project collaboration platform. He is also recognized as the inventor of a disaster response solution called the Butterfly House providing “folding houses” or rapid deployment shelter systems to disaster survivors.
In 2015, Santos was awarded the Ten Outstanding Young Men (TOYM) Award, the most prestigious award given in the Philippines. He has received two Senate Resolutions as recognition for his achievements. He has received many other notable awards including recognition from the New Jersey-based Ernst & Young and NJ Biz Magazine as one of New Jersey’s top 30 entrepreneurs. He has been featured on TED Talks and featured on major news outlets like the Wall Street Journal, CNN and Bloomberg.
Mr. Nelson has been active in the capital markets for the past 35 years. He began his financial career as a market representative with American International Group and in 1978 joined Dean Witter Reynolds as a Financial Advisor, working with high net worth and institutional clients. In 1980, he joined Drexel Burnham and Lambert, and subsequently, at Ladenberg, Thalmann, Auerbach Pollack and Richardson originating equity and investment banking transactions. Over the last 20 years, Mr. Nelson has led financing on many fintech, healthcare and bio-pharma companies through private equity and public financing including listings on the NASDAQ.
Mr. Nelson is responsible for advisory, merchant banking and general business developments for the Pacific Basin and Austral Asian markets. He holds a BA from Villanova University and an MBA from Rutgers University.
A globally recognized executive with extensive experience in Life Science, Medical Device industries with a focus on IT landscapes. Mark specializes in leading organizations through major transformations related to Blockchain, Digital Transformation and ERP programs. He currently leads the IT Advisory firm Ley-Line Advisory, Inc. as its CEO. Previous, he served as the CTO for Ernst & Young for over 10 years. He has also held global executive roles with industry leading firms including Novartis and Sony. With over thirty (30) years in complex global transformational programs, Mark has guided some of the largest transformations in the world along with various large Divestitures and Mergers.
Michelle is a blockchain and cryptocurrency entrepreneur. She is known to be one of the earliest female entrepreneurs in the Philippines’ crypto startup space and a bitcoin advocate since 2012, involved in various blockchain projects, including payment processors, remittance engines, exchanges, bespoke and enterprise blockchains. She is a partner at a crypto exchange with offices in the Philippines and Silicon Valley.
Michelle is also a seasoned print media content and editorial professional, holding various posts as contributing writer, official correspondent, columnist and editor. Her career in public relations and communications spans over a decade, with a clientele that includes companies in cosmetics, real estate, retail, banking and finance, healthcare and tech.
Brendan Sturm is a talented blockchain expert specializing in smart contract development, technical advising and product strategy. He has extensive experience helping teams design and build decentralized applications and has immersed himself in the blockchain space by founding active blockchain meetup groups in Washington DC. Some of Brendan’s previous projects include helping Cord design a smart contract based advertising exchange, building and deploying Uncloak’s token and crowdsale, and creating a tokenomic model for Atrium, a decentralized micro-task marketplace.
Tatiana Ovchinnikova is a dynamic leader, entrepreneur, quantitative analyst and mathematician currently focused on blockchain technology and fintech. Co-investment, partnership, strategic development, and technology are her areas of expertise. She is an advisor for several successful ICOs and STOs, holding a Masters in applied mathematics, MBA finance, AI and Data Science degrees from leading universities.
Dan has over 20 years’ experience in the management of BI and IT implementation in various industries, multi-location, and international environments. Experience encompasses all types of roles, including program and project management, strategy and architecture, and quality assurance.
He also served as the Global Business Intelligence Director for Interpublic Group, the 3rd largest Advertising and Media Communication Company in the world, with a presence in every country, and about 800 agencies and 40,000 employees globally.
Tom Eineker is an executive visionary known for delivering high-value ROI for SAP consulting services. His expertise includes strategy, execution and optimization of operational support services. Over the last 25 years, his accomplishments include implementation of SAP best practices and customized solutions for over 500 of the world’s industry-leading Global 2000 clients.
Dr. Eustaquio Abay is the founder of Abay Neuroscience Center beginning as a solo practice in 1986 and emerging to become the largest neurosurgery practice in the greater Wichita metropolitan area serving patients nationwide. Dr. Abay is a leading expert and practicing neurosurgeon. Currently serving on several boards in the healthcare, corporate, and non- profit sectors, he was named by Money Magazine as one of the top surgeons of the United States.
Dr. Peter Hans Frederikse is an Associate Professor of the Department of Oral Biology at the RBHS Dental School. He completed his Doctorate Degree in Microbiology at the University of Maryland in 1985. After which, he received his Post-Doctoral Fellowship in Molecular Microbiology from the Columbia University College of Physicians & Surgeons in 1989. He has received various awards and honors for his work such as the the Young Investigator Award in 1988, the National Foundation for Eye Research Award in 1995, and the International Society for Eye Research Fellowship Award in 1996. He was also named Associate Editor of the “Journal of Alzheimer’s Disease” in 2012. He has a considerable number of patents under his name, most of which are focused on ophthalmic health concerns and Alzheimer’s Disease.
Senior Director of Biopharmaceutical and Pharmaceutical Research and Development with 25 year track record managing and prioritizing multiple simultaneous projects. Served six years as Senior Director for Product Development, Process Development, Formulation Development, Analytical Science, Chemical Development and Protein Development at Stiefel, a GSK company, Barrier Therapeutics and Phyton Biotech, Inc.; five years as Director of Chemistry, Protein Development; and Analytical Biochemistry Research and Development at Phyton Biotech, Inc and MedImmune Inc.; and seven years as Manager of Chemical Development, Analytical Services (CDAS, with overall responsibilities for cGMP compliance and FDA interactions for SNDA filings), and registration services at Bristol-Myers Squibb.
Dr. Kasinathan is an Associate Professor in the Department of Oral Biology at the University of Medicine and Dentistry of New Jersey. He received his Doctorate Degree at the Postgraduate Institute of Medical Education and Research in Chandigarh, India in 1984. He completed his postdoctoral training in the Department of Physiology and Biophysics at Mount Sinai School of Medicine in New York before joining the Department of Oral Biology at New Jersey Dental School in 1988.